In Vitro Model for Analysis of High-Flow Aerosol Delivery During Continuous Nebulization
Overview
Affiliations
Background: To understand the fate of aerosols delivered by high-flow nasal cannula using continuous nebulization, an open-source anatomical model was developed and validated with a modified real-time gamma ratemeter technique. Mass balance defined circuit losses. Responsiveness to infusion rate and device technology were tested.
Methods: A nasal airway cast derived from a computed tomography scan was converted to a 3-dimensional-printed head and face structure connected to a piston ventilator (breathing frequency 30 breaths/min, tidal volume 750 mL, duty cycle 0.50). For mass balance experiments, saline mixed with Technetium-99m was infused for 1 h. Aerosol delivery was measured using a gamma ratemeter oriented to an inhaled mass filter at the hypopharynx of the model. Background and dead-space effects were minimized. All components were imaged by scintigraphy. Continuous nebulization was tested at infusion rates of 10-40 mL/h with gas flow of 60 L/min using a breath-enhanced jet nebulizer (BEJN), and a vibrating mesh nebulizer. Drug delivery rates were defined by the slope of ratemeter counts/min (CPM/min) versus time (min).
Results: The major source of aerosol loss was at the nasal interface (∼25%). Significant differences in deposition on circuit components were seen between nebulizers. The nebulizer residual was higher for BEJN ( = .006), and circuit losses, including the humidifier, were higher for vibrating mesh nebulizer ( = .006). There were no differences in delivery to the filter and head model. For 60 L/min gas flow, as infusion pump flow was increased, the rate of aerosol delivery (CPM/min) increased, for BEJN from 338 to 8,111; for vibrating mesh nebulizer, maximum delivery was 2,828.
Conclusions: The model defined sites of aerosol losses during continuous nebulization and provided a realistic in vitro system for testing aerosol delivery during continuous nebulization. Real-time analysis can quantify effects of multiple changes in variables (nebulizer technology, infusion rate, gas flow, and ventilation) during a given experiment.
In Vivo Deposition of High-Flow Nasal Aerosols Using Breath-Enhanced Nebulization.
Jayakumaran J, Smaldone G Pharmaceutics. 2024; 16(2).
PMID: 38399243 PMC: 10891871. DOI: 10.3390/pharmaceutics16020182.
Personalized Nasal Protective Devices: Importance and Perspectives.
Quoc T, Bacskay I, Feher P, Paller A, Papp B, Biro K Life (Basel). 2023; 13(11).
PMID: 38004256 PMC: 10672262. DOI: 10.3390/life13112116.
Innovation in Drug Delivery Through High-Flow Nasal Cannula Systems and Its Evaluation.
Berlinski A Respir Care. 2023; 68(9):1325-1326.
PMID: 37648444 PMC: 10468173. DOI: 10.4187/respcare.11295.
Enhanced Aerosol Delivery During High-Flow Nasal Cannula Therapy.
Moon J, McPeck M, Jayakumaran J, Smaldone G Respir Care. 2023; 68(9):1221-1228.
PMID: 37253612 PMC: 10468167. DOI: 10.4187/respcare.10644.